Dr. Eric Verdin on the Effects of Therapeutic Plasma Exchange on Longevity

Sep 3, 2025

Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging, delves into the fascinating world of therapeutic plasma exchange (TPE) and its potential to slow biological aging. He discusses groundbreaking findings from recent clinical trials that hint at measurable age reversal. The conversation highlights the importance of rigorous human trials in validating longevity treatments and the exciting possibilities of combining TPE with personalized lifestyle strategies for an extended healthspan.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Blood Contains Pro‑Aging And Rejuvenating Factors

Heterochronic parabiosis revealed circulating blood factors both add rejuvenating signals and dilute pro-aging ones.
Therapeutic plasma exchange (TPE) mimics the dilution/subtraction aspect in humans by replacing plasma while returning cells.

ADVICE

Demand Rigorous Placebo‑Controlled Trials

Run longevity interventions with rigorous, placebo‑controlled clinical trials to avoid hype and false claims.
Apply high scientific standards to validate efficacy before broad clinical adoption.

INSIGHT

Omics Require AI To Reveal Predictive Biology

Modern omics produce far more biomarkers than current clinical panels and enable precision aging profiles.
Integrating omics needs AI and knowledge graphs to reveal predictive relationships across layers.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

In this episode of Longevity by Design, Dr. Gil Blander welcomes Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging. Eric discusses the science behind therapeutic plasma exchange (TPE) and its potential to slow biological aging in humans. The conversation explores findings from a recent clinical trial, including measurable age reversal using epigenetic clocks.

Eric explains how removing and replacing plasma can dilute pro-aging factors in the blood, a concept inspired by earlier animal studies on parabiosis. He also describes why rigorous, placebo-controlled human trials are crucial for validating longevity interventions and distinguishing the field from hype-driven wellness trends.

The episode also highlights how omics data, such as metabolomics and proteomics, are shaping a new era of precision aging research. Eric emphasizes the value of lifestyle interventions as a foundation and sees future opportunities in combining TPE with personalized strategies to extend healthspan.

Guest-at-a-Glance

💡 Name: Dr. Eric Verdin

💡 What they do: President and CEO

💡 Company: Buck Institute for Research on Aging

💡 Noteworthy: Physician-scientist pioneering human aging research through epigenetics, metabolism, and translational science.

💡 Where to find him: LinkedIn

Episode highlights:

[00:00] Introduction to Longevity and Healthspan
[01:07] Meet Dr. Eric Verde: A Pioneer in Aging Research
[02:24] Exploring Therapeutic Plasma Exchange
[03:08] The Science Behind Heterochronic Parabiosis
[07:17] Clinical Trials and Methodologies
[12:58] The Role of Omics in Precision Medicine
[17:20] Epigenetic Clocks and Aging
[22:04] Therapeutic Plasma Exchange: Results and Implications
[26:22] Exploring Frequency and Efficacy of Treatments
[28:23] Biomarkers and Predictive Models
[31:33] Safety Profile and Side Effects
[33:28] Intrinsic Capacity and Aging Metrics
[36:58] Combining Treatments with Lifestyle Changes
[44:26] Future Directions and Recommendations
[49:08] Conclusion and Final Thoughts

We Appreciate You!
As a token of our gratitude, we’re excited to offer you 15% off your next purchase. Simply click the link below to redeem your discount: https://info.insidetracker.com/podcast

For science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast